AstraZeneca studies nurandociguat drug interactions with rosuvastatin, dabigatran
Summary
AstraZeneca registered a Phase I clinical trial on ClinicalTrials.gov investigating potential drug interactions between nurandociguat and two established medications—rosuvastatin (a statin) and dabigatran (an anticoagulant). The single-arm study will evaluate pharmacokinetic parameters in healthy participants to assess how co-administration affects drug exposure and safety profiles.
What changed
AstraZeneca added a new clinical trial registration (NCT07515339) to the ClinicalTrials.gov database documenting a drug interaction study for nurandociguat with rosuvastatin and dabigatran. The registry entry includes standard trial metadata including phase, design, and participant criteria.
For pharmaceutical manufacturers and clinical research organizations, this registration represents routine transparency in drug development pipelines. While the study itself is informational, it signals AstraZeneca's commitment to characterizing the safety profile of nurandociguat ahead of potential regulatory submissions, including required drug-drug interaction assessments under FDA guidelines.
What to do next
- Monitor trial progress on ClinicalTrials.gov
Source document (simplified)
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.